Reverse Medical Corporation Announces New Patent For The Micro Vascular Plug (MVP®)

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

IRVINE, Calif.--(BUSINESS WIRE)--Reverse Medical Corporation announced today that the United States Patent Office has notified the Company that a new patent has issued entitled “Embolic Implant and Method of Use”. This new patent allows twenty-two claims surrounding the Company’s Micro Vascular Plug (“MVP”) technology platform. The Reverse Medical MVP represents a proprietary technology designed specifically for vascular embolization. A number of clinical applications require occlusion of the vasculature to rapidly, effectively and safely provide blood flow cessation, including presentations of trauma, hemorrhage, tumor and vascular malformation isolations. Physicians have traditionally used embolic coils for vascular embolization, often requiring numerous costly implants, extensive endovascular lab time and considerable fluoroscopic radiation exposure to both the patient and the treating medical staff. The Reverse Medical MVP represents a breakthrough technology that rapidly occludes target blood vessels, most often with only one single implant. Furthermore, the MVP is uniquely deliverable through traditional microcatheters, allowing the physician to super-selectively perform rapid vascular embolization at the target vessel location. The MVP technology platform will be offered in a variety of sizes to treat all areas of the body’s peripheral vasculature.

Help employers find you! Check out all the jobs and post your resume.

Back to news